Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Pfizer (NYSE:PFE) and maintained a $45 price target.
October 23, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Louise Chen has reiterated an Overweight rating on Pfizer, maintaining a $45 price target. This suggests confidence in Pfizer's stock performance.
The reiteration of an Overweight rating and maintenance of a $45 price target by a reputable analyst suggests a positive outlook for Pfizer's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100